PAI

Palo Alto Investors Portfolio holdings

AUM $470M
1-Year Return 2.57%
This Quarter Return
+1.52%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$887M
AUM Growth
-$223M
Cap. Flow
-$96M
Cap. Flow %
-10.82%
Top 10 Hldgs %
73.36%
Holding
40
New
6
Increased
12
Reduced
9
Closed
2

Top Buys

1
SLRN
ACELYRIN
SLRN
+$11.6M
2
ELEV
Elevation Oncology
ELEV
+$6.91M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.23M
4
NUVB icon
Nuvation Bio
NUVB
+$2.81M
5
ANAB icon
AnaptysBio
ANAB
+$2.55M

Top Sells

1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$32M
2
INSM icon
Insmed
INSM
+$29.5M
3
UTHR icon
United Therapeutics
UTHR
+$29.4M
4
BIIB icon
Biogen
BIIB
+$19.5M
5
FOLD icon
Amicus Therapeutics
FOLD
+$12.1M

Sector Composition

1 Healthcare 98.15%
2 Financials 1.85%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
ELEV
26
DELISTED
Elevation Oncology
ELEV
$6.91M 0.78%
+1,346,666
New +$6.91M
BLUE
27
DELISTED
bluebird bio
BLUE
$5.84M 0.66%
228,009
+61,342
+37% +$1.57M
RLMD icon
28
Relmada Therapeutics
RLMD
$52.8M
$3.41M 0.38%
732,400
– –
NUVB icon
29
Nuvation Bio
NUVB
$1.07B
$2.81M 0.32%
+772,652
New +$2.81M
TSHA icon
30
Taysha Gene Therapies
TSHA
$837M
$2.33M 0.26%
811,268
+281,407
+53% +$808K
STOK icon
31
Stoke Therapeutics
STOK
$1.29B
$1.7M 0.19%
+125,861
New +$1.7M
MIRM icon
32
Mirum Pharmaceuticals
MIRM
$3.73B
$1.63M 0.18%
64,700
– –
HUM icon
33
Humana
HUM
$33.2B
$1.38M 0.16%
+3,985
New +$1.38M
VYNE icon
34
VYNE Therapeutics
VYNE
$7.91M
$1.37M 0.15%
445,434
– –
TVTX icon
35
Travere Therapeutics
TVTX
$2.09B
$854K 0.1%
110,719
– –
ALDX icon
36
Aldeyra Therapeutics
ALDX
$324M
$737K 0.08%
225,465
– –
ACRS icon
37
Aclaris Therapeutics
ACRS
$211M
$707K 0.08%
+569,832
New +$707K
URGN icon
38
UroGen Pharma
URGN
$869M
$368K 0.04%
24,500
– –
SGHT icon
39
Sight Sciences
SGHT
$181M
– –
-173,790
Closed -$897K
VNDA icon
40
Vanda Pharmaceuticals
VNDA
$266M
– –
-278,985
Closed -$1.18M
1
2